Bausch + Lomb Corporation (BLCO) AI Stock Analysis

• Market Cap: $6.01B
• Dividend Yield: N/A
• Average Volume (3M): 441.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 6.23%
• EPS Growth: 17.53%
• Country: US
• Employees: 13,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.18
• Shares Outstanding: 354,189,800
• 10 Day Avg. Volume: 396,785
• 30 Day Avg. Volume: 441,036
• PEG Ratio: -0.93
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 1.33
• P/FCF Ratio: -107.69
• Enterprise Value/Market Cap: 1.67
• Enterprise Value/Revenue: 2.02
• Enterprise Value/Gross Profit: 3.39
• Enterprise Value/Ebitda: 19.70
• 1Y Price Target: $17.09
• Price Target Upside: 0.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 0.53
• Revenue Forecast (FY): $5.08B

• Rating: 61 Neutral
• Price Target: $17.50 ▲(3.06% Upside)

Bausch + Lomb's overall stock score is driven by strong technical indicators and positive strategic outlook from recent corporate events. However, financial performance and valuation concerns, particularly negative profitability and cash flow issues, weigh down the score.

Positive Factors

Revenue Growth

Consistent revenue growth across segments indicates strong market demand and effective product strategies, supporting long-term business expansion.

Strategic Growth Plan

The strategic growth plan with a focus on innovation and AI positions the company for sustainable growth and competitive advantage.

Pharmaceutical Segment Success

Strong performance in the pharmaceutical segment, particularly with Miebo, highlights successful product innovation and market penetration.

Negative Factors

Negative Profit Margins

Negative net profit margins indicate ongoing operational challenges, which could hinder long-term financial health and shareholder returns.

Weak Cash Flow Performance

Weak cash flow performance limits the company's ability to invest in growth opportunities and manage financial obligations effectively.

Mixed Gross Margin Performance

Declining gross margins suggest cost management issues, which could impact profitability and competitive pricing strategies.

Bausch + Lomb Corporation Business Overview & Revenue Model

Company Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

How the Company Makes Money

Bausch + Lomb generates revenue through several key streams, including the sale of contact lenses and lens care products, surgical products, and pharmaceutical solutions for eye health. The contact lens segment, which includes daily disposable and specialty lenses, represents a significant portion of the company's income. Additionally, the surgical division, which provides equipment and consumables for cataract and refractive surgery, contributes to its earnings. The company also engages in partnerships with healthcare providers and distributors to expand its market reach and enhance its product offerings. Furthermore, Bausch + Lomb invests in research and development to innovate new products, which helps maintain its competitive edge and drive long-term revenue growth.

Bausch + Lomb Corporation Financial Statement Overview

Summary

Bausch + Lomb Corporation faces challenges in profitability and cash flow, despite stable revenue growth and a solid equity base. The company needs to improve operational efficiency and cash generation to enhance financial health and shareholder returns.

Income Statement

Bausch + Lomb Corporation shows modest revenue growth in the TTM, but profitability remains a concern with negative net profit margins. The gross profit margin is stable, indicating efficient cost management, but the EBIT and EBITDA margins have declined, reflecting operational challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate, suggesting a balanced approach to leveraging. However, the negative return on equity indicates challenges in generating returns for shareholders. The equity ratio is healthy, showing a strong equity base relative to total assets.

Cash Flow

Cash flow performance is weak, with negative free cash flow and low operating cash flow coverage. The free cash flow to net income ratio is concerning, highlighting cash generation issues. Despite some growth in free cash flow, overall cash flow stability is lacking.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.98B	4.79B	4.15B	3.77B	3.77B	3.41B
Gross Profit	2.96B	2.92B	2.50B	2.25B	2.30B	2.13B
EBITDA	509.00M	601.00M	499.00M	598.00M	733.00M	732.00M
Net Income	-305.00M	-317.00M	-260.00M	6.00M	182.00M	-18.00M
Balance Sheet
Total Assets	13.83B	13.47B	13.44B	11.14B	10.82B	11.27B
Cash, Cash Equivalents and Short-Term Investments	310.00M	305.00M	334.00M	380.00M	174.00M	238.00M
Total Debt	4.95B	4.94B	4.68B	2.55B	140.00M	101.00M
Total Liabilities	7.33B	6.92B	6.52B	4.04B	1.42B	1.28B
Stockholders Equity	6.43B	6.47B	6.85B	7.03B	9.33B	9.92B
Cash Flow
Free Cash Flow	-194.47M	-59.00M	-198.00M	170.00M	680.00M	263.00M
Operating Cash Flow	171.05M	232.00M	-17.00M	345.00M	873.00M	522.00M
Investing Cash Flow	-452.30M	-412.00M	-2.11B	-215.00M	-214.00M	-256.00M
Financing Cash Flow	254.45M	178.00M	2.08B	81.00M	-712.00M	-232.00M

Bausch + Lomb Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLCO, the sentiment is Positive. The current price of 16.98 is above the 20-day moving average (MA) of 16.36, above the 50-day MA of 15.75, and above the 200-day MA of 14.12, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 58.51 is Neutral, neither overbought nor oversold. The STOCH value of 58.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLCO.

Bausch + Lomb Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COO	76 Outperform	$15.88B	44.02	4.59%	―	5.06%	-4.47%
MMSI	68 Neutral	$5.15B	44.65	8.30%	―	11.49%	-2.89%
RGEN	68 Neutral	$8.90B	6,105.84	0.08%	―	11.74%	―
STVN	67 Neutral	$5.70B	36.72	9.81%	0.29%	9.19%	23.06%
BLCO	61 Neutral	$6.01B	-19.54	-4.69%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XRAY	46 Neutral	$2.27B	-2.58	-44.44%	5.61%	-7.08%	-113.81%

Bausch + Lomb Corporation Corporate Events

Bausch + Lomb Unveils Strategic Growth Plan at Investor Day

On November 13, 2025, Bausch + Lomb Corporation announced its plans during an Investor Day event at the New York Stock Exchange, highlighting a transformation in its operations and a focus on sustainable growth. The company revealed a three-year plan targeting above-market revenue growth and margin expansion, driven by innovations in its eye health product pipeline. The event emphasized Bausch + Lomb’s commitment to leveraging AI and new technologies, with projected peak sales of pipeline products expected to reach approximately $7 billion. The company aims for a 5-7% revenue CAGR through 2028, with significant product launches anticipated across various segments, reaffirming its 2025 guidance and positioning itself for long-term value creation for shareholders.